Solid Tumor, Unspecified, Adult

Oncology
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Arcus Biosciences
1 program
1
DomvanalimabPhase 1Monoclonal Antibody
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
DomvanalimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03628677Completed75Est. Jan 2025
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
RLY-1971Phase 11 trial
Active Trials
NCT04252339Completed56Est. Nov 2022
Artios Pharma
Artios PharmaUK - Cambridge
1 program
Determination of ATM alteration status.N/A1 trial
Active Trials
NCT04976803Completed229Est. Jun 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RocheRLY-1971
Gilead SciencesDomvanalimab
Artios PharmaDetermination of ATM alteration status.

Clinical Trials (3)

Total enrollment: 360 patients across 3 trials

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Start: Feb 2020Est. completion: Nov 202256 patients
Phase 1Completed

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Start: Sep 2018Est. completion: Jan 202575 patients
Phase 1Completed
NCT04976803Artios PharmaDetermination of ATM alteration status.

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

Start: May 2021Est. completion: Jun 2022229 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space